FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808776157> ?p ?o ?g. }

• W2808776157 endingPage "6545" @default.
• W2808776157 startingPage "6527" @default.
• W2808776157 abstract "Because complement activation in the subacute or chronic phase after stroke was recently shown to stimulate neural plasticity, we investigated how complement activation and complement inhibition in the acute phase after murine stroke interacts with subsequent rehabilitation therapy to modulate neuroinflammation and neural remodeling. We additionally investigated how complement and complement inhibition interacts with tissue plasminogen activator (tPA), the other standard of care therapy for stroke, and a U.S. Food and Drug Administration preclinical requirement for translation of an experimental stroke therapy. CR2fH, an injury site-targeted inhibitor of the alternative complement pathway, significantly reduced infarct volume, hemorrhagic transformation, and mortality and significantly improved long-term motor and cognitive performance when administered 1.5 or 24 h after middle cerebral artery occlusion. CR2fH interrupted a poststroke inflammatory process and significantly reduced inflammatory cytokine release, microglial activation, and astrocytosis. Rehabilitation alone showed mild anti-inflammatory effects, including reduced complement activation, but only improved cognitive recovery. CR2fH combined with rehabilitation significantly potentiated cognitive and motor recovery compared with either intervention alone and was associated with higher growth factor release and enhanced rehabilitation-induced neuroblast migration and axonal remodeling. Similar outcomes were seen in adult, aged, and female mice. Using a microembolic model, CR2fH administered in combination with acute tPA therapy improved overall survival and enhanced the neuroprotective effects of tPA, extending the treatment window for tPA therapy. A human counterpart of CR2fH has been shown to be safe and nonimmunogenic in humans and we have demonstrated robust deposition of C3d, the CR2fH targeting epitope, in ischemic human brains after stroke. <b>SIGNIFICANCE STATEMENT</b> Complement inhibition is a potential therapeutic approach for stroke, but it is not known how complement inhibition would interact with current standards of care. We show that, after murine ischemic stroke, rehabilitation alone induced mild anti-inflammatory effects and improved cognitive, but not motor recovery. However, brain-targeted and specific inhibition of the alternative complement pathway, when combined with rehabilitation, significantly potentiated cognitive and motor recovery compared with either intervention alone via mechanisms involving neuroregeneration and enhanced brain remodeling. Further, inhibiting the alternative pathway of complement significantly enhanced the neuroprotective effects of thrombolytic therapy and markedly expanded the therapeutic window for thrombolytic therapy." @default.
• W2808776157 created "2018-06-29" @default.
• W2808776157 creator A5025657878 @default.
• W2808776157 creator A5044573364 @default.
• W2808776157 creator A5063647013 @default.
• W2808776157 creator A5069525702 @default.
• W2808776157 date "2018-06-19" @default.
• W2808776157 modified "2023-10-18" @default.
• W2808776157 title "Acute Complement Inhibition Potentiates Neurorehabilitation and Enhances tPA-Mediated Neuroprotection" @default.
• W2808776157 cites W1833364259 @default.
• W2808776157 cites W1992751386 @default.
• W2808776157 cites W1994971232 @default.
• W2808776157 cites W1995830102 @default.
• W2808776157 cites W1999495459 @default.
• W2808776157 cites W2011783556 @default.
• W2808776157 cites W2012087896 @default.
• W2808776157 cites W2033102468 @default.
• W2808776157 cites W2034684388 @default.
• W2808776157 cites W2039526488 @default.
• W2808776157 cites W2044273548 @default.
• W2808776157 cites W2045421141 @default.
• W2808776157 cites W2050180933 @default.
• W2808776157 cites W2067361755 @default.
• W2808776157 cites W2082748157 @default.
• W2808776157 cites W2085434701 @default.
• W2808776157 cites W2102406427 @default.
• W2808776157 cites W2105414745 @default.
• W2808776157 cites W2132328499 @default.
• W2808776157 cites W2140632361 @default.
• W2808776157 cites W2143317925 @default.
• W2808776157 cites W2149600133 @default.
• W2808776157 cites W2150593929 @default.
• W2808776157 cites W2152202709 @default.
• W2808776157 cites W2154702871 @default.
• W2808776157 cites W2155162743 @default.
• W2808776157 cites W2160959923 @default.
• W2808776157 cites W2219068693 @default.
• W2808776157 cites W2223549218 @default.
• W2808776157 cites W2253366929 @default.
• W2808776157 cites W2332374153 @default.
• W2808776157 cites W2345329114 @default.
• W2808776157 cites W2507824981 @default.
• W2808776157 cites W2564623825 @default.
• W2808776157 cites W2570547106 @default.
• W2808776157 cites W2735185933 @default.
• W2808776157 cites W2780318688 @default.
• W2808776157 cites W4236993511 @default.
• W2808776157 cites W2162183922 @default.
• W2808776157 doi "https://doi.org/10.1523/jneurosci.0111-18.2018" @default.
• W2808776157 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6052238" @default.
• W2808776157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29921716" @default.
• W2808776157 hasPublicationYear "2018" @default.
• W2808776157 type Work @default.
• W2808776157 sameAs 2808776157 @default.
• W2808776157 citedByCount "19" @default.
• W2808776157 countsByYear W28087761572018 @default.
• W2808776157 countsByYear W28087761572019 @default.
• W2808776157 countsByYear W28087761572020 @default.
• W2808776157 countsByYear W28087761572021 @default.
• W2808776157 countsByYear W28087761572022 @default.
• W2808776157 countsByYear W28087761572023 @default.
• W2808776157 crossrefType "journal-article" @default.
• W2808776157 hasAuthorship W2808776157A5025657878 @default.
• W2808776157 hasAuthorship W2808776157A5044573364 @default.
• W2808776157 hasAuthorship W2808776157A5063647013 @default.
• W2808776157 hasAuthorship W2808776157A5069525702 @default.
• W2808776157 hasBestOaLocation W28087761571 @default.
• W2808776157 hasConcept C111684460 @default.
• W2808776157 hasConcept C126322002 @default.
• W2808776157 hasConcept C127413603 @default.
• W2808776157 hasConcept C15744967 @default.
• W2808776157 hasConcept C169760540 @default.
• W2808776157 hasConcept C1862650 @default.
• W2808776157 hasConcept C203014093 @default.
• W2808776157 hasConcept C25498285 @default.
• W2808776157 hasConcept C2776572282 @default.
• W2808776157 hasConcept C2776914184 @default.
• W2808776157 hasConcept C2778818304 @default.
• W2808776157 hasConcept C2780645631 @default.
• W2808776157 hasConcept C47177892 @default.
• W2808776157 hasConcept C71924100 @default.
• W2808776157 hasConcept C78519656 @default.
• W2808776157 hasConcept C87753298 @default.
• W2808776157 hasConcept C8891405 @default.
• W2808776157 hasConcept C98274493 @default.
• W2808776157 hasConceptScore W2808776157C111684460 @default.
• W2808776157 hasConceptScore W2808776157C126322002 @default.
• W2808776157 hasConceptScore W2808776157C127413603 @default.
• W2808776157 hasConceptScore W2808776157C15744967 @default.
• W2808776157 hasConceptScore W2808776157C169760540 @default.
• W2808776157 hasConceptScore W2808776157C1862650 @default.
• W2808776157 hasConceptScore W2808776157C203014093 @default.
• W2808776157 hasConceptScore W2808776157C25498285 @default.
• W2808776157 hasConceptScore W2808776157C2776572282 @default.
• W2808776157 hasConceptScore W2808776157C2776914184 @default.
• W2808776157 hasConceptScore W2808776157C2778818304 @default.
• W2808776157 hasConceptScore W2808776157C2780645631 @default.
• W2808776157 hasConceptScore W2808776157C47177892 @default.

• next